-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since December 2019, COVID-19 has spread rapidly around the world.
As of September 19, 2021, there have been more than 225 million confirmed cases and nearly 4.
7 million deaths
.
Patients with heart disease are considered to be at high risk of adverse outcomes after being hospitalized for COVID-19
COVID-19
Recently, the heart blood vessels magazine field authority Eur Heart published a research article on J, the purpose of this study was to evaluate the association between the heterogeneity of the various subtypes of heart disease in patients with in-hospital mortality
.
The researchers used data from the CAPACITY-COVID Registry and the LEOSS study, and fitted a multivariate Poisson regression model to assess the association between different types of heart disease and hospital mortality
.
The study included 16511 COVID-19 patients (21.
1% of the patients were 66-75 years old; 40.
2% were women), and 31.
5% of the subjects had a history of heart disease
.
Patients with heart disease are older, mainly male, and usually have other comorbidities compared with patients without heart disease
diagnosis
It can be seen that there is considerable heterogeneity in the strength of the association between heart disease subtypes and hospital mortality
.
Among all heart disease patients, patients with heart failure are at the greatest risk of death due to COVID-19 hospitalization
There is considerable heterogeneity in the strength of the association between heart disease subtypes and hospital mortality
Original source:
The CAPACITY-COVID Collaborative Consortium and LEOSS Study Group.
Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries in this message